Alnylam Pharmaceuticals
Biopharmaceutical company pioneering RNA interference (RNAi) therapeutics to treat rare and prevalent genetic diseases.
About
Alnylam Pharmaceuticals is a commercial-stage biopharmaceutical company that develops innovative therapies based on RNA interference (RNAi). By silencing disease-causing genes at the genetic level, the company provides transformative treatments for patients with rare and common genetic, metabolic, and cardiovascular diseases.
Technology stack
detected 2026-06-04Est. monthly stack spend~$140/mo
Email
Mimecast
gateway-fronted
Hosting
self_managed
Stack
jQuery
Bootstrap
Frequently asked
What does Alnylam Pharmaceuticals do?
Alnylam Pharmaceuticals is a commercial-stage biopharmaceutical company that develops innovative therapies based on RNA interference (RNAi). By silencing disease-causing genes at the genetic level, the company provides transformative treatments for patients with rare and common genetic, metabolic, and cardiovascular diseases.
Where is Alnylam Pharmaceuticals headquartered?
Alnylam Pharmaceuticals is headquartered in Cambridge, Massachusetts, United States.
When was Alnylam Pharmaceuticals founded?
Alnylam Pharmaceuticals was founded in 2002.
What industry does Alnylam Pharmaceuticals operate in?
Alnylam Pharmaceuticals operates in Biotechnology, Pharmaceuticals, Healthcare.